Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy

Терапевтический архив

V. V. Ptushkin¹  E. V. Gapchenko²  D. A. Kudlay²  A. Yu. Borozinets²  O. A. Markova²  N. V. Minaeva³  E. A. Lukina⁴  A. D. Kulagin⁵  V. S. Shamrai⁶  I. L. Davydkin⁷  T. S. Konstantinova⁸ 

[1] Botkin City Clinical Hospital;JSC GENERIUM;Kirov Research Institute of Hematology and Blood Transfusion;National Hematology Medical Research Center;Pavlov First Saint Petersburg State Medical University;Rostov Regional Clinical Hospital;Samara State Medical University;Sverdlovsk Regional Clinical Hospital №1;

关键词: paroxysmal nocturnal hemoglobinuria;    complement system;    eculizumab;    elizaria;    safety;    pharmacokinetics;    pharmacodynamics;   

DOI  :  10.26442/00403660.2020.07.000818

来源: DOAJ

【 授权许可】

Unknown